Open EyeBeta

A public record of U.S. government and large ownership

Brand

DARZALEX

DARZALEX is a treatment for multiple myeloma, also sold as DARZALEX FASPRO. Johnson & Johnson's fiscal 2025 Form 10-K says Genmab owns related patent families and Janssen Biotech, a wholly owned subsidiary, has an exclusive license. The royalty rate is 12% to 20% of DARZALEX net sales.

PharmaceuticalsHealthcare

Also searched as DARZALEX FASPRO, daratumumab.

Documented stakes

  • Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies. Janssen Biotech, Inc., described as a wholly owned subsidiary, has an exclusive license from Genmab. Royalties are 12% to 20% of DARZALEX net sales.

    As of Dec 28, 2025. Last checked Sep 22, 2026.